All In Biotech

Drug Trial Radar · NCT02607956

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 657 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

657

Actual

Start

Nov 11, 2015

Primary completion

May 12, 2017

Study completion Jul 5, 2021

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.

Conditions

  • HIV-1 Infection

Interventions

  • DTGDrug

    50 mg tablets administered orally, once daily

  • F/TAFDrug

    200/25 mg tablets administered orally, once daily

  • B/F/TAFDrug

    50/200/25 milligrams (mg) FDC tablets administered orally, once daily

  • DTG PlaceboDrug

    Tablets administered orally, once daily

  • F/TAF PlaceboDrug

    Tablets administered orally, once daily

  • B/F/TAF PlaceboDrug

    Tablets administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmTime frame: Week 48

Locations

125 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    Sacramento, California

  • Optimus Medical - ClinEdge - PPDS

    San Francisco, California

  • Kaiser Permanente

    San Leandro, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    DeLand, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Ft. Pierce, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Oakland Park, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Sinai Hospital of Baltimore

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Berkley, Michigan

  • Site not named

    Detroit, Michigan

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.